TA239 Breast cancer (metastatic) - fulvestrant: review proposal - August 2014

Review of NICE Technology Appraisal Guidance No.239; Fulvestrant for the treatment of locally advanced or metastatic breast cancer

Proposal to move the existing guidance to the static list

The planned date for review of the above guidance is August 2014.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

Since the publication of TA239, no new evidence has emerged that would lead to a change in the existing recommendations.  Consequently we propose that TA239 should move to the static list of technology appraisals.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.  Please see appendix A for a full list of the organisations we have contacted. 

August 2014


This page was last updated: 16 August 2014